Mifepristone — Discount Pricing

Other medications in Women's Health

• Misoprostol Cervical
• Nifedipine (Tocolytic)
• Norethindrone-Ethinyl Estradiol
• Oxytocin
• Progesterone Vaginal
• Relugolix
• Terbutaline
• Betamethasone Prenatal

What Mifepristone is approved for (FDA label)

Mifepristone tablets, 200 mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. Mifepristone tablets, 200 mg is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: June 6, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Mifepristone (FDA label)

WARNING: SERIOUS AND SOMETIMES FATAL INFECTIONS OR BLEEDING Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following Mifepristone tablets, 200 mg use. No causal relationship between the use of Mifepristone tablets, 200 mg and misoprostol and these events has been established. Atypical Presentation of Infection. Patients with serious bacterial infections (e.g., Clostridium sordellii ) and sepsis can present without fever, bacteremia, or significant findings on pelvic examination following an abortion. Very rarely, deaths have been reported in patients who presented without fever, with or without abdominal pain, but with leukocytosis with a marked left shift, tachycardia, hemoconcentration, and general malaise. A high index of suspicion is needed to rule out serious infection and sepsis [see Warnings and Precautions ( 5.1 )] Bleeding. Prolonged heavy bleeding may be a sign of incomplete abortion or other complications and prompt medical or surgical intervention may be needed. Advise patients to seek immediate medical attention if they experience prolonged heavy vaginal bleeding [see Warnings and Precautions ( 5.2 )]. Because of the risks of serious complications described above, Mifepristone tablets, 200mg is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Mifepristone REMS Program [see Warnings and Precautions ( 5.3 )]. Before prescribing Mifepristone, inform the patient about the risk of these serious events.

Source: FDA prescribing information (DailyMed). Set ID: b63fad9b-7f12-4400-9019-b0586054e534. SPL document ID: 539725c1-189c-1934-e063-6294a90ac3c0. Label effective date: June 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Mifepristone (FDA label)

Tablets containing 200 mg of mifepristone each, supplied as 1 tablet on one blister card. Mifepristone tablets are light yellow in color, circular, bio-convex tablets, approximately 11mm in diameter and imprinted on one side with “S.” Tablets containing 200 mg of mifepristone each, supplied as 1 tablet on one blister card (3)

Source: FDA prescribing information (DailyMed). Set ID: b63fad9b-7f12-4400-9019-b0586054e534. SPL document ID: 539725c1-189c-1934-e063-6294a90ac3c0. Label effective date: June 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Mifepristone (FDA label)

The following adverse reactions are described in greater detail in other sections: Infection and sepsis [ see Warnings and Precautions ( 5.1 )] Uterine bleeding [ see Warnings and Precautions ( 5.2 )] Most common adverse reactions (>15%) are nausea, weakness, fever/chills, vomiting, headache, diarrhea, and dizziness. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact GenBioPro, Inc. at 1-855-643-3463 or medical@genbiopro.com or www.MIFEINFO.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: b63fad9b-7f12-4400-9019-b0586054e534. SPL document ID: 539725c1-189c-1934-e063-6294a90ac3c0. Label effective date: June 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Mifepristone (FDA label)

Administration of Mifepristone tablets, 200 mg and misoprostol for the termination of pregnancy (the “treatment procedure”) is contraindicated in patients with any of the following conditions: Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (the treatment procedure will not be effective to terminate an ectopic pregnancy) [ see Warnings and Precautions ( 5.4 )] Chronic adrenal failure (risk of acute adrenal insufficiency) Concurrent long-term corticosteroid therapy (risk of acute adrenal insufficiency) History of allergy to mifepristone, misoprostol, or other prostaglandins (allergic reactions including anaphylaxis, angioedema, rash, hives, and itching have been reported [ see Adverse Reactions ( 6.2 )]) Hemorrhagic disorders or concurrent anticoagulant therapy (risk of heavy bleeding) Inherited porphyrias (risk of worsening or of precipitation of attacks) Use of Mifepristone tablets, 200 mg and misoprostol for termination of intrauterine pregnancy is contraindicated in patients with an intrauterine device (“IUD”) in place (the IUD might interfere with pregnancy termination).

Source: FDA prescribing information (DailyMed). Set ID: b63fad9b-7f12-4400-9019-b0586054e534. SPL document ID: 539725c1-189c-1934-e063-6294a90ac3c0. Label effective date: June 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Mifepristone (FDA label)

Ectopic pregnancy: Exclude before treatment. ( 5.4 ) Rhesus immunization: Prevention needed as for surgical abortion. ( 5.5 ) 5.1 Infection and Sepsis As with other types of abortion, cases of serious bacterial infection, including very rare cases of fatal septic shock, have been reported following the use of Mifepristone tablets, 200 mg [see Boxed Warning ]. Healthcare providers evaluating a patient who is undergoing a medical abortion should be alert to the possibility of this rare event. A sustained (>4 hours) fever of 100.4°F or higher, severe abdominal pain, or pelvic tenderness in the days after a medical abortion may be an indication of infection. A high index of suspicion is needed to rule out sepsis (e.g., from Clostridium sordellii ) if a patient reports abdominal pain or discomfort or general malaise (including weakness, nausea, vomiting or diarrhea) more than 24 hours after taking misoprostol.

Source: FDA prescribing information (DailyMed). Set ID: b63fad9b-7f12-4400-9019-b0586054e534. SPL document ID: 539725c1-189c-1934-e063-6294a90ac3c0. Label effective date: June 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Mifepristone (FDA label)

CYP3A4 inducers can lower mifepristone concentrations. ( 7.1 ) CYP3A4 inhibitors can increase mifepristone concentrations. Use with caution. ( 7.2 ) CYP3A4 substrate concentrations can be increased. Caution with coadministration of substrates with narrow therapeutic margin. ( 7.3 ) 7.1 Drugs that May Reduce Mifepristone tablets, 200 mg Exposure (Effect of CYP 3A4 Inducers on Mifepristone tablets, 200mg) CYP450 3A4 is primarily responsible for the metabolism of mifepristone. CYP3A4 inducers such as rifampin, dexamethasone, St. John's Wort, and certain anticonvulsants (such as phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum concentrations of mifepristone). Whether this action has an impact on the efficacy of the dose regimen is unknown.

Source: FDA prescribing information (DailyMed). Set ID: b63fad9b-7f12-4400-9019-b0586054e534. SPL document ID: 539725c1-189c-1934-e063-6294a90ac3c0. Label effective date: June 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.